Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells

S. Dasgupta, Lori Tabor Wasson, N. Rauniyar, Laszlo Prokai, Julian Borejdo, Jamboor K. Vishwanatha

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

C17orf37/MGC14832, a novel gene located on human chromosome 17q12 in the ERBB2 amplicon, is abundantly expressed in breast cancer. C17orf37 expression has been reported to positively correlate with grade and stage of cancer progression; however the functional significance of C17orf37 overexpression in cancer biology is not known. Here, we show that C17orf37 is highly expressed in prostate cancer cell lines and tumors, compared to minimal expression in normal prostate cells and tissues. Cellular localization studies by confocal and total internal reflection fluorescence microscopy revealed predominant expression of C17orf37 in the cytosol with intense staining in the membrane of prostate cancer cells. RNA-interference-mediated downregulation of C17orf37 resulted in decreased migration and invasion of DU-145 prostate cancer cells, and suppressed the DNA-binding activity of nuclear factor-κB (NF-κB) transcription factor resulting in reduced expression of downstream target genes matrix metalloproteinase 9, urokinase plasminogen activator and vascular endothelial growth factor. Phosphorylation of PKB/Akt was also reduced upon C17orf37 downregulation, suggesting C17orf37 acts as a signaling molecule that increases invasive potential of prostate cancer cells by NF-κB-mediated downstream target genes. Our data strongly suggest C17orf37 overexpression in prostate cancer functionally enhances migration and invasion of tumor cells, and is an important target for cancer therapy.

Original languageEnglish
Pages (from-to)2860-2872
Number of pages13
JournalOncogene
Volume28
Issue number32
DOIs
StatePublished - 13 Aug 2009

Fingerprint

Prostatic Neoplasms
Complement Factor B
Genes
Neoplasms
Down-Regulation
Plasminogen Activators
Matrix Metalloproteinase 9
Urokinase-Type Plasminogen Activator
Human Chromosomes
RNA Interference
Tumor Cell Line
Fluorescence Microscopy
Cytosol
Vascular Endothelial Growth Factor A
Prostate
Transcription Factors
Phosphorylation
Staining and Labeling
Breast Neoplasms
Membranes

Keywords

  • 17q12
  • C17orf37
  • Invasion
  • Migration
  • NF-κB
  • Prostate cancer

Cite this

@article{174c4d89d9c14d32aa2cc41a41bee714,
title = "Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells",
abstract = "C17orf37/MGC14832, a novel gene located on human chromosome 17q12 in the ERBB2 amplicon, is abundantly expressed in breast cancer. C17orf37 expression has been reported to positively correlate with grade and stage of cancer progression; however the functional significance of C17orf37 overexpression in cancer biology is not known. Here, we show that C17orf37 is highly expressed in prostate cancer cell lines and tumors, compared to minimal expression in normal prostate cells and tissues. Cellular localization studies by confocal and total internal reflection fluorescence microscopy revealed predominant expression of C17orf37 in the cytosol with intense staining in the membrane of prostate cancer cells. RNA-interference-mediated downregulation of C17orf37 resulted in decreased migration and invasion of DU-145 prostate cancer cells, and suppressed the DNA-binding activity of nuclear factor-κB (NF-κB) transcription factor resulting in reduced expression of downstream target genes matrix metalloproteinase 9, urokinase plasminogen activator and vascular endothelial growth factor. Phosphorylation of PKB/Akt was also reduced upon C17orf37 downregulation, suggesting C17orf37 acts as a signaling molecule that increases invasive potential of prostate cancer cells by NF-κB-mediated downstream target genes. Our data strongly suggest C17orf37 overexpression in prostate cancer functionally enhances migration and invasion of tumor cells, and is an important target for cancer therapy.",
keywords = "17q12, C17orf37, Invasion, Migration, NF-κB, Prostate cancer",
author = "S. Dasgupta and Wasson, {Lori Tabor} and N. Rauniyar and Laszlo Prokai and Julian Borejdo and Vishwanatha, {Jamboor K.}",
year = "2009",
month = "8",
day = "13",
doi = "10.1038/onc.2009.145",
language = "English",
volume = "28",
pages = "2860--2872",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "32",

}

Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. / Dasgupta, S.; Wasson, Lori Tabor; Rauniyar, N.; Prokai, Laszlo; Borejdo, Julian; Vishwanatha, Jamboor K.

In: Oncogene, Vol. 28, No. 32, 13.08.2009, p. 2860-2872.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells

AU - Dasgupta, S.

AU - Wasson, Lori Tabor

AU - Rauniyar, N.

AU - Prokai, Laszlo

AU - Borejdo, Julian

AU - Vishwanatha, Jamboor K.

PY - 2009/8/13

Y1 - 2009/8/13

N2 - C17orf37/MGC14832, a novel gene located on human chromosome 17q12 in the ERBB2 amplicon, is abundantly expressed in breast cancer. C17orf37 expression has been reported to positively correlate with grade and stage of cancer progression; however the functional significance of C17orf37 overexpression in cancer biology is not known. Here, we show that C17orf37 is highly expressed in prostate cancer cell lines and tumors, compared to minimal expression in normal prostate cells and tissues. Cellular localization studies by confocal and total internal reflection fluorescence microscopy revealed predominant expression of C17orf37 in the cytosol with intense staining in the membrane of prostate cancer cells. RNA-interference-mediated downregulation of C17orf37 resulted in decreased migration and invasion of DU-145 prostate cancer cells, and suppressed the DNA-binding activity of nuclear factor-κB (NF-κB) transcription factor resulting in reduced expression of downstream target genes matrix metalloproteinase 9, urokinase plasminogen activator and vascular endothelial growth factor. Phosphorylation of PKB/Akt was also reduced upon C17orf37 downregulation, suggesting C17orf37 acts as a signaling molecule that increases invasive potential of prostate cancer cells by NF-κB-mediated downstream target genes. Our data strongly suggest C17orf37 overexpression in prostate cancer functionally enhances migration and invasion of tumor cells, and is an important target for cancer therapy.

AB - C17orf37/MGC14832, a novel gene located on human chromosome 17q12 in the ERBB2 amplicon, is abundantly expressed in breast cancer. C17orf37 expression has been reported to positively correlate with grade and stage of cancer progression; however the functional significance of C17orf37 overexpression in cancer biology is not known. Here, we show that C17orf37 is highly expressed in prostate cancer cell lines and tumors, compared to minimal expression in normal prostate cells and tissues. Cellular localization studies by confocal and total internal reflection fluorescence microscopy revealed predominant expression of C17orf37 in the cytosol with intense staining in the membrane of prostate cancer cells. RNA-interference-mediated downregulation of C17orf37 resulted in decreased migration and invasion of DU-145 prostate cancer cells, and suppressed the DNA-binding activity of nuclear factor-κB (NF-κB) transcription factor resulting in reduced expression of downstream target genes matrix metalloproteinase 9, urokinase plasminogen activator and vascular endothelial growth factor. Phosphorylation of PKB/Akt was also reduced upon C17orf37 downregulation, suggesting C17orf37 acts as a signaling molecule that increases invasive potential of prostate cancer cells by NF-κB-mediated downstream target genes. Our data strongly suggest C17orf37 overexpression in prostate cancer functionally enhances migration and invasion of tumor cells, and is an important target for cancer therapy.

KW - 17q12

KW - C17orf37

KW - Invasion

KW - Migration

KW - NF-κB

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=68949086106&partnerID=8YFLogxK

U2 - 10.1038/onc.2009.145

DO - 10.1038/onc.2009.145

M3 - Article

C2 - 19503095

AN - SCOPUS:68949086106

VL - 28

SP - 2860

EP - 2872

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 32

ER -